Anuncia Inc

Anuncia Inc. specializes in developing medical devices aimed at treating cerebrospinal fluid (CSF) disorders, such as hydrocephalus, which require draining or shunting of CSF. The company's flagship product, the ReFlow Ventricular System, is FDA cleared and CE Marked, designed to facilitate a safe, noninvasive retrograde fluid flush when ventriculoperitoneal shunt flow is restricted or blocked. This system is a prescription device sold by or on the order of a physician and is intended for use by qualified clinicians. Anuncia Inc. is also developing the ReFlow System Mini, which has received FDA Breakthrough Device Designation but is not yet available for sale. The company operates in the MedTech market, targeting healthcare providers and institutions that treat patients with CSF disorders. Anuncia Inc. generates revenue through the sale of its medical devices, leveraging its innovative technology to address critical needs in the treatment of CSF disorders. The company has been recognized with awards such as the Fast Company 2021 World Changing Ideas Award, highlighting its impact and potential in the medical technology field.

Keywords: cerebrospinal fluid, hydrocephalus, noninvasive, FDA-cleared, MedTech, retrograde fluid flush, prescription device, healthcare, innovation, breakthrough technology.